Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin Glycoprotein of Influenza A Virus (HA)
- Target
- HA
- Molecular classification
- Viral Protein, Glycoprotein, Class I transmembrane glycoprotein
01
Overview
Hemagglutinin glycoprotein (HA) enables influenza virus entry by mediating both attachment to sialylated receptors on host cells via its globular head domain and subsequent pH-triggered membrane fusion through its stem region. Its high variability drives antigenic evolution while conserved domains offer targets for broad-spectrum vaccines. As such, it remains central to influenza pathogenesis, immunity, diagnostics, surveillance efforts—and ongoing therapeutic innovation.
- Other names
- HAInfluenza HemagglutininHemagglutininHA protein
02
Mechanism of action
Neutralizing antibodies block receptor binding or inhibit conformational changes required for fusion.
03
Biological functions
Receptor bindingMembrane fusionViral entryImmune response
04
Disease associations
InfectionInfluenzaViral pathogenesis
05
Safety considerations
Antigenic drift/shift leading to immune escapePotential for antibody-dependent enhancement (ADE)Risk of zoonotic transmission
06
Interacting drugs
NA
1 more in the full profile.
07
Biomarkers
HA sequence (for subtype identification)Antibody titers against HA (for vaccine efficacy)HA mutations (for drug resistance)
Beyond the preview
Go deeper on Hemagglutinin Glycoprotein of Influenza A Virus (HA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemagglutinin Glycoprotein of Influenza A Virus (HA).